Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan could spare thousands from unnecessary kidney surgery

NCT ID NCT06076538

Diagnosis Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This study is testing whether a combined PET and MRI scan (PET/MR) can better tell apart aggressive kidney cancers from slow-growing or harmless tumors. About 97 adults with a suspicious kidney mass will receive the scan during their regular MRI appointment. Researchers hope this approach reduces unnecessary surgeries by improving how doctors identify which tumors truly need treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FDG (a radioactive tracer) and furosemide (a diuretic)
What this could lead to
If successful, this could lead to a more accurate imaging method to distinguish aggressive kidney cancers from slow-growing or benign tumors, helping avoid unnecessary treatments.
What could go wrong
This is an early observational study with only 97 participants, so results may not apply to everyone. The scan uses radiation and may not be widely available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 97 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2023

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Eligible patients will complete their clinically indicated MRI with the addition of the research infusion of the FDA approved FDG radiotracer and PET portion of the scan. Eligibility waivers are not permitted. Subjects must meet all of the inclusion and exclusion criteria to be registered to the study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with known solid (\>25% total volume enhances) renal mass * Renal mass size measuring \>2 to ≤7 cm * Age \>18 years * Ability to understand and the willingness to sign a written informed consent. Exclusion Criteria: * Pregnancy * Prior percutaneous biopsy of the renal mass * Prior treatment of the renal mass * Prior hemorrhage in the renal mass * Contraindication to MRI or PET * Renal mass not eligible for ccLS based on prior imaging (i.e., containing macroscopic fat \[classic angiomyolipoma\] or enhancing less than 25% of its volume \[considered a cystic renal mass\]) * Genetic syndrome predisposing to renal masses (e.g., VHL, BHD, TSC, etc.); * More than 3 renal masses at time of initial diagnosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Renal cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

kidney benign neoplasm kidney neoplasm renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Renal cell carcinoma Renal tumor Renal tumor, benign

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The University of Texas MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • University of Texas Southwestern Medical Center

    RECRUITING

    Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.